JP2021529732A5 - - Google Patents

Info

Publication number
JP2021529732A5
JP2021529732A5 JP2020569956A JP2020569956A JP2021529732A5 JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5 JP 2020569956 A JP2020569956 A JP 2020569956A JP 2020569956 A JP2020569956 A JP 2020569956A JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5
Authority
JP
Japan
Prior art keywords
administration
pharmaceutical composition
composition according
esketamine
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020569956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529732A (ja
JP7903800B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/055453 external-priority patent/WO2020003195A1/en
Publication of JP2021529732A publication Critical patent/JP2021529732A/ja
Publication of JP2021529732A5 publication Critical patent/JP2021529732A5/ja
Priority to JP2024000939A priority Critical patent/JP2024041855A/ja
Application granted granted Critical
Publication of JP7903800B2 publication Critical patent/JP7903800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020569956A 2018-06-27 2019-06-27 大うつ病性障害の処置方法 Active JP7903800B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000939A JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862690419P 2018-06-27 2018-06-27
US62/690,419 2018-06-27
US201862698323P 2018-07-16 2018-07-16
US62/698,323 2018-07-16
US201862741564P 2018-10-05 2018-10-05
US62/741,564 2018-10-05
US201862769264P 2018-11-19 2018-11-19
US62/769,264 2018-11-19
PCT/IB2019/055453 WO2020003195A1 (en) 2018-06-27 2019-06-27 Method of treating major depressive disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000939A Division JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Publications (3)

Publication Number Publication Date
JP2021529732A JP2021529732A (ja) 2021-11-04
JP2021529732A5 true JP2021529732A5 (cg-RX-API-DMAC7.html) 2022-04-25
JP7903800B2 JP7903800B2 (ja) 2026-08-12

Family

ID=67909427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020569956A Active JP7903800B2 (ja) 2018-06-27 2019-06-27 大うつ病性障害の処置方法
JP2024000939A Pending JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000939A Pending JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Country Status (11)

Country Link
US (2) US12036189B2 (cg-RX-API-DMAC7.html)
EP (1) EP3813807B1 (cg-RX-API-DMAC7.html)
JP (2) JP7903800B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793535B1 (cg-RX-API-DMAC7.html)
CN (1) CN112188889A (cg-RX-API-DMAC7.html)
AU (1) AU2019293515B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023882A2 (cg-RX-API-DMAC7.html)
CA (1) CA3103440A1 (cg-RX-API-DMAC7.html)
IL (1) IL278759B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020012475A (cg-RX-API-DMAC7.html)
WO (1) WO2020003195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
WO2021137147A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー. 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
WO2004004693A1 (en) 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
JP2009530385A (ja) 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
CN105534936B (zh) 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
WO2009137843A2 (en) 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
WO2013138322A1 (en) 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
KR20220044380A (ko) 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
WO2015066172A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3272338B1 (en) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Oral dosage form of ketamine
EP3193853A1 (en) * 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
KR102604397B1 (ko) 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
WO2018079693A1 (ja) 2016-10-27 2018-05-03 国立大学法人 千葉大学 (s)-ノルケタミンおよびその塩の医薬品としての応用
WO2018102488A1 (en) 2016-11-30 2018-06-07 Wolfson Philip E Ketamine for the treatment of menstrually related symptoms
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3923920A4 (en) 2019-08-05 2022-11-23 The Ketamine Research Foundation KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Similar Documents

Publication Publication Date Title
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
Montgomery et al. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
Cutler et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
BR112020023882A2 (pt) método para tratar transtorno depressivo maior
Silva Filho et al. Comment on “The importance of physical exercise during the coronavirus (COVID-19) pandemic”
Lu et al. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series
EP3393517B1 (en) Acetylsalicylic acid for use in the treatment of moderate to severe influenza
JP7034314B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
JP2022503771A5 (cg-RX-API-DMAC7.html)
Alavi et al. Tranquilizer/Anxiolytics: Pregabalin
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
Bedard et al. P0174-Mindfulness-based cognitive therapy reduces depression symptoms in people with a traumatic brain injury: Results from a pilot study
Sharma et al. POS-416 TREATING HCV INFECTION IN CHRONIC KIDNEY DISEASE IN DEVELOPING COUNTRY: OUR EXPERIENCE WITH LIMITED RESOURCES
RU2000129499A (ru) Лечение депрессии и фармацевтические препараты для этой цели
Cooper et al. Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)
Zhang et al. A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis
Downey A New Way To Manage Depression Without Drugs
Vieta Why do we consider major depressive disorder to be a chronic illness?
Palmer Olanzapine/fluoxetine promising in hard-to-treat depression
TW202539680A (zh) 組合物在製備用於治療至少一種癌症的用途
Bauer et al. P0173-Effect of once-daily extended release Quetiapine Fumarate (Quetiapine XR) as add-on to antidepressants in major depressive disorder (MDD)
Glynn et al. Combining herbs and drugs–at times a fractious marriage
Bostankolu Aripiprazole/fluoxetine/sertraline interaction